- Home
- GITS vs THAR Comparison
GITS vs THAR Comparison
Compare GITS & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GITS
- THAR
- Stock Information
- Founded
- GITS 2018
- THAR 2017
- Country
- GITS South Korea
- THAR United States
- Employees
- GITS N/A
- THAR N/A
- Industry
- GITS
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- GITS
- THAR Health Care
- Exchange
- GITS Nasdaq
- THAR Nasdaq
- Market Cap
- GITS 4.8M
- THAR 4.0M
- IPO Year
- GITS N/A
- THAR 2022
- Fundamental
- Price
- GITS $1.17
- THAR $1.29
- Analyst Decision
- GITS
- THAR Strong Buy
- Analyst Count
- GITS 0
- THAR 1
- Target Price
- GITS N/A
- THAR $17.00
- AVG Volume (30 Days)
- GITS 76.9K
- THAR 135.2K
- Earning Date
- GITS 11-20-2024
- THAR 05-08-2025
- Dividend Yield
- GITS N/A
- THAR N/A
- EPS Growth
- GITS N/A
- THAR N/A
- EPS
- GITS N/A
- THAR N/A
- Revenue
- GITS N/A
- THAR N/A
- Revenue This Year
- GITS N/A
- THAR N/A
- Revenue Next Year
- GITS N/A
- THAR N/A
- P/E Ratio
- GITS N/A
- THAR N/A
- Revenue Growth
- GITS 85.47
- THAR N/A
- 52 Week Low
- GITS $0.10
- THAR $1.20
- 52 Week High
- GITS $5.06
- THAR $7.13
- Technical
- Relative Strength Index (RSI)
- GITS N/A
- THAR 35.72
- Support Level
- GITS N/A
- THAR $1.20
- Resistance Level
- GITS N/A
- THAR $1.65
- Average True Range (ATR)
- GITS 0.00
- THAR 0.15
- MACD
- GITS 0.00
- THAR -0.00
- Stochastic Oscillator
- GITS 0.00
- THAR 18.40
About GITS Global Interactive Technologies Inc. Common Stock
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.